Bladder cancer, especially non muscle invasive bladder cancer (NMIBC), is the most common malignant tumor of the urinary system. Although cisplatin based chemotherapy has shown significant clinical efficacy as a first-line treatment, its therapeutic effect is still limited for patients with lymphatic vascular invasion (LVI).

The formation of LVI is closely related to platelets, which not only hinder drug delivery but also protect tumor cells from chemotherapy-induced cell death and immune attacks. Therefore, inhibiting platelet function has become a key strategy to prevent LVI formation and enhance cisplatin anti-tumor activity.

On August 13, 2024, Nano Letters reported that researchers have designed siliceous bodies modified with CREKA peptides（ CREKA@LPT-MSNC ）Nanodrugs achieve targeted inhibition of LVI formation and significantly improve the chemotherapy effect of bladder cancer.

This nanomedicine has a core-shell structure, where tirofiban is preferentially loaded into the CREKA modified liposome shell, while cisplatin is embedded in the mesoporous silica nanoparticle core. Experimental results have shown that, CREKA@LPT-MSNC Nanoparticles not only prolong blood circulation, but also have excellent tumor targeting ability, which helps to increase drug concentration at the tumor site while reducing the side effects of antiplatelet therapy.
The anti-tumor effect in vivo shows that, CREKA@LPT-MSNC Effectively inhibited the formation of LVI and increased the permeability of tumor blood vessels, thereby improving the drug delivery efficiency within the tumor, promoting the exposure of tumor cells to cisplatin, and ultimately improving the therapeutic effect of cisplatin. In addition, the nanomedicine also has an effective inhibitory effect on tumor metastasis, demonstrating excellent biosafety and biocompatibility.

This study not only provides new ideas and methods for the precise treatment of bladder cancer, but also provides a model for the treatment of other types of tumors.

From Article:Targeted Inhibition of Lymphovascular Invasion Formation with CREKA Peptide-Modified Silicasomes to Boost Chemotherapy in Bladder Cancer

SAT NANO is a best supplier of mesoporous silica nanoparticle in China, we can supply 60-80nm, 100-150nm. If you have any enquiry, please feel free to contact us at admin@satnano.com